213 related articles for article (PubMed ID: 25907261)
21. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
22. Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in Addis Ababa, Ethiopia.
Kassa A; Teka A; Shewaamare A; Jerene D
Trans R Soc Trop Med Hyg; 2012 Jun; 106(6):363-70. PubMed ID: 22521216
[TBL] [Abstract][Full Text] [Related]
23. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
24. [Clinical management of acute and chronic human immunodeficiency virus infection before starting antiretroviral treatment].
Miró JM; Manzardo C; Zamora L; Pumarola T; Herreras Z; Gallart T; Gatell JM
Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):759-72. PubMed ID: 22078726
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
Zhang S; van Sighem A; Gras L; Reiss P; Smit C; Kroon F; Jurriaans S; Prins J; Lange J; de Wolf F
Antivir Ther; 2010; 15(4):555-62. PubMed ID: 20587848
[TBL] [Abstract][Full Text] [Related]
26. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
27. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
[TBL] [Abstract][Full Text] [Related]
28. Development of tuberculosis in human immunodeficiency virus infected patients receiving antiretroviral therapy.
Martín-Echevarria E; Serrano-Villar S; Sainz T; Moreno A; Casado JL; Dronda F; Elías MJ; Navas E; Zapata MR; Moreno S
Int J Tuberc Lung Dis; 2014 Sep; 18(9):1080-4. PubMed ID: 25189556
[TBL] [Abstract][Full Text] [Related]
29. Predictors of immunological failure and determinants of suboptimal CD4 testing among adults with HIV on first-line antiretroviral therapy in Andhra Pradesh, India, 2008-2011.
Allam RR; Murhekar MV; Bhatnagar T; Uthappa CK; Nalini C; Rewari BB; Mehendale SM
Trans R Soc Trop Med Hyg; 2015 May; 109(5):325-33. PubMed ID: 25778736
[TBL] [Abstract][Full Text] [Related]
30. Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.
Neilan AM; Karalius B; Patel K; Van Dyke RB; Abzug MJ; Agwu AL; Williams PL; Purswani M; Kacanek D; Oleske JM; Burchett SK; Wiznia A; Chernoff M; Seage GR; Ciaranello AL;
JAMA Pediatr; 2017 May; 171(5):450-460. PubMed ID: 28346597
[TBL] [Abstract][Full Text] [Related]
31. CD4+ T-cell recovery and clinical outcome in HIV-1-infected patients exposed to multiple antiretroviral regimens: partial control of viremia is associated with favorable outcome.
Brigido L; Rodrigues R; Casseb J; Custodio RM; Fonseca LA; Sanchez M; Duarte AJ
AIDS Patient Care STDS; 2004 Apr; 18(4):189-98. PubMed ID: 15142349
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
[TBL] [Abstract][Full Text] [Related]
33. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy.
Gotti D; Danesi M; Calabresi A; Ferraresi A; Albini L; Donato F; Castelli F; Scalzini A; Quiros-Roldan E;
AIDS Patient Care STDS; 2013 May; 27(5):259-65. PubMed ID: 23600703
[TBL] [Abstract][Full Text] [Related]
35. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
36. Episodes of HIV viremia and the risk of non-AIDS diseases in patients on suppressive antiretroviral therapy.
Zhang S; van Sighem A; Kesselring A; Gras L; Smit C; Prins JM; Kauffmann R; Richter C; de Wolf F; Reiss P
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):265-72. PubMed ID: 22531756
[TBL] [Abstract][Full Text] [Related]
37. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
[TBL] [Abstract][Full Text] [Related]
39. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
Miller V; Staszewski S; Sabin C; Carlebach A; Rottmann C; Weidmann E; Rabenau H; Hill A; Lepri AC; Phillips AN
J Infect Dis; 1999 Aug; 180(2):530-3. PubMed ID: 10395876
[TBL] [Abstract][Full Text] [Related]
40. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Côte d'Ivoire.
Seyler C; Anglaret X; Dakoury-Dogbo N; Messou E; Touré S; Danel C; Diakité N; Daudié A; Inwoley A; Maurice C; Tonwe-Gold B; Rouet F; N'Dri-Yoman T; Salamon R;
Antivir Ther; 2003 Oct; 8(5):385-93. PubMed ID: 14640385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
